Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

The Effect of Option Homogeneity in Multiple-Choice Items.

Applegate GM, Sutherland KA, Becker KA, Luo X.

Appl Psychol Meas. 2019 Mar;43(2):113-124. doi: 10.1177/0146621618770803. Epub 2018 May 7.

PMID:
30792559
2.

A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages.

Mlcochova P, Sutherland KA, Watters SA, Bertoli C, de Bruin RA, Rehwinkel J, Neil SJ, Lenzi GM, Kim B, Khwaja A, Gage MC, Georgiou C, Chittka A, Yona S, Noursadeghi M, Towers GJ, Gupta RK.

EMBO J. 2017 Mar 1;36(5):604-616. doi: 10.15252/embj.201696025. Epub 2017 Jan 25.

3.

Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.

Sutherland KA, Collier DA, Claiborne DT, Prince JL, Deymier MJ, Goldstein RA, Hunter E, Gupta RK.

Sci Rep. 2016 Nov 30;6:38153. doi: 10.1038/srep38153.

4.

Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.

Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks CF, Goodall R, Spyer M, Kityo C, Pillay D, Gupta RK; DART Virology Group.

PLoS One. 2016 Jun 2;11(6):e0157094. doi: 10.1371/journal.pone.0157094. eCollection 2016.

5.

Viraemia and Ebola virus secretion in survivors of Ebola virus disease in Sierra Leone: a cross-sectional cohort study.

Green E, Hunt L, Ross JCG, Nissen NM, Curran T, Badhan A, Sutherland KA, Richards J, Lee JS, Allen SH, Laird S, Blackman M, Collacott I, Parker PA, Walbridge A, Phillips R, Sellu SJ, Dama A, Sheriff AK, Zombo J, Ngegba D, Wurie AH, Checchi F, Brooks TJ.

Lancet Infect Dis. 2016 Sep;16(9):1052-1056. doi: 10.1016/S1473-3099(16)30060-3. Epub 2016 May 17.

PMID:
27197552
6.

A Review of Tools to Assist Hospitals in Meeting Community Health Assessment and Implementation Strategy Requirements.

Schifferdecker KE, Bazos DA, Sutherland KA, Ayers LaFave LR, Ruggles L, Fedrizzi R, Hoebeke J.

J Healthc Manag. 2016 Jan-Feb;61(1):44-56. Review.

7.

Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.

Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks CF, Goodall R, Spyer M, Kityo C, Pillay D, Gupta RK; DART Virology Group.

PLoS One. 2015 Sep 18;10(9):e0137834. doi: 10.1371/journal.pone.0137834. eCollection 2015. Erratum in: PLoS One. 2016;11(6):e0157094.

8.

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.

Sutherland KA, Goodall RL, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Thiltgen G, Gilks CF, Spyer M, Kityo C, Pillay D, Dunn D, Gupta RK; DART Virology Group; DART Trial Team.

AIDS Res Hum Retroviruses. 2015 Oct;31(10):1032-7. doi: 10.1089/aid.2015.0138. Epub 2015 Aug 10.

9.

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.

Sutherland KA, Ghosn J, Gregson J, Mbisa JL, Chaix ML, Cohen Codar I, Delfraissy JF, Delaugerre C, Gupta RK.

J Antimicrob Chemother. 2015 Jan;70(1):243-8. doi: 10.1093/jac/dku365. Epub 2014 Sep 16.

10.

Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes.

Sutherland KA, Mbisa JL, Ghosn J, Chaix ML, Cohen-Codar I, Hue S, Delfraissy JF, Delaugerre C, Gupta RK.

J Antimicrob Chemother. 2014 Dec;69(12):3340-8. doi: 10.1093/jac/dku296. Epub 2014 Aug 4.

11.

Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1.

Sutherland KA, Mbisa JL, Cane PA, Pillay D, Parry CM.

J Gen Virol. 2014 Jan;95(Pt 1):190-200. doi: 10.1099/vir.0.055624-0. Epub 2013 Oct 30.

PMID:
24172906
12.

Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.

Dolling DI, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, Post FA, Sabin CA, Cane PA; UK HIV Drug Resistance Database (UKHDRD); UK Collaborative HIV Cohort Study (UK CHIC).

J Antimicrob Chemother. 2013 Oct;68(10):2339-43. doi: 10.1093/jac/dkt199. Epub 2013 May 27.

13.

Frequent users of an inner-city emergency department.

Geurts J, Palatnick W, Strome T, Sutherland KA, Weldon E.

CJEM. 2012 Sep;14(5):306-13. Erratum in: CJEM. 2016 Jan;18(1):80. Sutherland, Karen Anne [added].

PMID:
22967698
14.

RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.

Sutherland KA, Rogers HL, Tosh D, Rogers MJ.

Arthritis Res Ther. 2009;11(2):R58. doi: 10.1186/ar2681. Epub 2009 Apr 30.

15.
16.

MAL6 of Saccharomyces: a complex genetic locus containing three genes required for maltose fermentation.

Needleman RB, Kaback DB, Dubin RA, Perkins EL, Rosenberg NG, Sutherland KA, Forrest DB, Michels CA.

Proc Natl Acad Sci U S A. 1984 May;81(9):2811-5.

Supplemental Content

Loading ...
Support Center